WFH news
-
WFH WBDR 2018 Data Report now published
The WFH World Bleeding Disorders Registry (WBDR) 2018 Data Report now available! This report is based on 1,181 patients who were enrolled between January and December 2018. As of...
-
WFH welcomes Bayer to Humanitarian Aid Program
The WFH Humanitarian Aid Program aims to improve the lack of access to care and treatment for people with inherited bleeding disorders in developing countries,...
-
Now available: WFH Humanitarian Aid Program Impact Report 2018
A new report—called the “WFH Humanitarian Aid Program: Impact Report 2018”—has just been released. The document shows the impact that the WFH Humanitarian Aid Program...
-
Collaboration announced between St. Jude Children’s Research Hospital and WFH
The WFH is proud to announce that we will be collaborating with St. Jude Children’s Research Hospital in order to establish a gene therapy clinical...
-
GAP supports outreach and identification in Jordan and Egypt
The Global Alliance for Progress (GAP) Program is designed to greatly increase the diagnosis and treatment of people with hemophilia and other bleeding disorders in...
-
Twinning Program leads to successful outreach in Mauritius
The Mauritian World Federation of Hemophilia (WFH) national member organization (NMO) successfully executed an outreach and identification campaign in the country which found 15 new...
-
Haemophilia Journal article details WFH Humanitarian Aid Program achievements
An article published in the journal Haemophilia covers the many accomplishments the WFH Humanitarian Aid Program made possible in 2016. In “First-year results of an...
-
Roche joins the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program aims to improve the lack of access to care and treatment for people with inherited bleeding disorders in developing countries,...
-
CSL Behring today renews commitment to WFH
CSL Behring today announced that the company has renewed its commitment as a Visionary Corporate Partner with the WFH for another three years. This is...
-
WFH Medical Advisory Board (MAB) supports MASAC’s recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #255 entitled, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia...
